The global G protein-coupled receptor (GPCR) market is expected to grow from $4.4 billion in 2024 and is projected to reach $6.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2024 to 2029.
The GPCR-targeting technologies market was $4.1 billion in 2023 and is expected to grow at a CAGR of 6.8% during the forecast period to reach $6.1 billion by the end of 2029. Drivers of the market’s growth include technological advances, the growing prevalence of chronic diseases, rising demand for GPCR drugs, R&D, the expansion of GPCR applications in drug discovery, diagnostics and clinical trials, and government initiatives.
The regions looked at are North America (the U.S., Canada and Mexico), Europe (Germany, the U.K., France, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Singapore and Rest of APAC) and the Rest of the World (South America, the Middle East and Africa). The report also includes profiles of leading companies and discusses industry trends, significant products, mergers and acquisitions, and other collaborations or partnerships.
The GPCR-targeting technologies market was $4.1 billion in 2023 and is expected to grow at a CAGR of 6.8% during the forecast period to reach $6.1 billion by the end of 2029. Drivers of the market’s growth include technological advances, the growing prevalence of chronic diseases, rising demand for GPCR drugs, R&D, the expansion of GPCR applications in drug discovery, diagnostics and clinical trials, and government initiatives.
Report Scope
This report on the global market for G protein-coupled receptor (GPCR) targeting technologies analyzes the current landscape, including market size and growth trends and segments the market by assay type, product type, application and region. Assay categories include cAMP assays and cGMP assays, calcium functional assays, arrestin functional assays, radioligand binding and GTPgammaS functional assays, reporter gene assays and others. Product types include cell lines, detection kits, cell culture reagents and ligands. Applications include oncology, cardiovascular diseases (CVDs), central nervous system diseases, respiratory diseases and others.The regions looked at are North America (the U.S., Canada and Mexico), Europe (Germany, the U.K., France, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Singapore and Rest of APAC) and the Rest of the World (South America, the Middle East and Africa). The report also includes profiles of leading companies and discusses industry trends, significant products, mergers and acquisitions, and other collaborations or partnerships.
The report includes:
- 22 data tables and 43 additional tables
- An analysis of the global market and technologies for G-protein coupled receptor (GPCR) targeting
- Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Evaluation of the market potential for GPCR targeting technology, industry growth drivers, and forecasts for this market’s segments and sub-segments
- Estimates of the market size and revenue forecast for the global GPCR targeting technology market in USD millions, and a corresponding market share analysis by assay type, product type, application and region
- Discussion of the major market dynamics and shifts, and the regulations, industry challenges and macroeconomic factors affecting the demand for GPCR targeting technology over the coming years
- A look at the recent technological breakthroughs in the use of GPCR targeting technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
- Review of the patent filings and research publications for innovations in GPCR targeting technology
- Discussion on the industry’s ESG challenges and practices
- Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances or other advantages
- Insights into the industry structure for GPCR targeting technology, the competitive landscape, clinical trials and ongoing research activity
- Profiles of the major players in the industry, including Promega Corp., Revvity Inc., Thermo Fisher Scientific Inc., Enzo Biochem Inc., and Danaher Corp.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Emerging Technologies and Developments
Chapter 5 Market Segmentation Analysis
Chapter 6 Competitive Intelligence
Chapter 7 Sustainability in the GPCR-Targeting Technologies Industry: An ESG Perspective
Chapter 8 Appendix
List of Tables
List of Figures
Companies Mentioned
- Agilent Technologies Inc.
- BD
- Danaher Corp.
- Enzo Biochem Inc.
- Epics Therapeutics
- Eurofins Scientific
- Interax Biotech AG
- Merck KGaA
- Orion Biotechnology Canada Ltd.
- Promega Corp.
- Qiagen
- Revvity
- Tectonic Therapeutic
- Thermo Fisher Scientific Inc.
- Wuxi Apptec
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 107 |
| Published | April 2025 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value ( USD | $ 4.4 Billion |
| Forecasted Market Value ( USD | $ 6.1 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
